Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | CTSS | P25774 | 9/20 | 0.65 |
| ▸ | CTSK | P43235 | 8/20 | 0.65 |
| ▸ | CTSB | P07858 | 3/20 | 0.63 |
| ▸ | CTSL | P07711 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | FPR2 | P25090 | 4/20 | 0.56 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28773022 | 1.00 | HDAC8 (0.66) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL30134897 | 1.00 | HDAC8 (0.66) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3944495 | 0.92 | HDAC8 (0.72) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL9610766 | 0.92 | HDAC8 (0.72) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL23466658 | 0.90 | CTSS (0.65) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL23466656 | 0.90 | CTSS (0.65) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3667405 | 0.89 | HDAC8 (0.64) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3667404 | 0.89 | HDAC8 (0.64) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL30135039 | 0.89 | CTSS (0.63) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3006410 | 0.88 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| WO-2022216717-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | HDAC8 1078/4885CTSS 3694/4885CTSK 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.